LEADER 01811oam  2200541   450 
001 9910711779603321
005 20220408143846.0
035   $a(CKB)5470000002486273
035   $a(OCoLC)1080339765
035   $a(EXLCZ)995470000002486273
100   $a20181228d2018      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aExamining patient access to investigational drugs $ehearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session. October 3, 2017
210  1$aWashington :$cU.S. Government Publishing Office,$d2018.
215   $a1 online resource (iv, 235 pages) $cphotographs
300   $a"Serial No. 115-60."
320   $aIncludes bibliographical references.
517   $aExamining patient access to investigational drugs 
606   $aClinical trials$zUnited States
606   $aClinical trials$xMoral and ethical aspects$zUnited States
606   $aDrugs$zUnited States$xTesting
606   $aDrugs$xTesting$xMoral and ethical aspects$zUnited States
608   $aLegislative hearings.$2lcgft
615  0$aClinical trials
615  0$aClinical trials$xMoral and ethical aspects
615  0$aDrugs$xTesting.
615  0$aDrugs$xTesting$xMoral and ethical aspects
801  0$bGPO
801  1$bGPO
801  2$bGPO
801  2$bMERUC
801  2$bIAD
801  2$bOCLCO
801  2$bUPM
801  2$bOCLCF
801  2$bSOI
801  2$bOCLCO
801  2$bIAS
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910711779603321
996   $aExamining patient access to investigational drugs$93515940
997   $aUNINA